Vaccine rollout has started in many countries. In Italy, the Covid-19 vaccine used at the moment is the mRNA-based BNT162b2 and is given to Hospital employers. The investigators undertake this study to monitor IgG evolution after vaccination in the participant hospital settings, which includes 500 subjects.
Vaccine rollout has started in many countries. In Italy, the Covid-19 vaccine used at the
moment is the mRNA-based BNT162b2 and is given to Hospital employers.
The investigators undertake this observational study to monitor antibody evolution after
vaccination in a hospital setting. The primary endpoint is serum IgG at the first month of
2nd jab, and at 3, 6, and 12 months afterward.
As secondary measures, nasopharyngeal swabs are included, at fortnight intervals to detects
the spike protein antigen, in the event that putative vaccine inefficacy would expose the
health personnel to Covid-19 disease with potential spreading to inpatients.
Further, clinical signs and symptoms are monitored at the weekly interval in the context of
adverse reactions/events.
Biological: BNT162b2 mRNA Covid-19 Vaccine
Hospital employers vaccinated with BNT162b2 mRNA against Sars-Cov2 are studied for serum antibody response.
Inclusion Criteria:
- Hospital employers vaccinated against Sars-Cov2
Exclusion Criteria:
- none
ICOT-Sapienza University Hospital
Latina, LT, Italy
Investigator: Lugi Iuliano, M.D.
Contact: +393406462332
luigi.iuliano@uniroma1.it
Lugi Iuliano, M.D.
+393406462332
luigi.iuliano@uniroma1.it
Alessandro Polidoro, M.D.
+393478115718
alessandro.polidoro@uniroma1.it
Luigi Iuliano, M.D., Principal Investigator
University of Roma La Sapienza